Therapeutic composiitons comprising bactericidal/permeability-increasing (BPI) protein products

Abstract

Improved therapeutic compositions having enhanced anti-microbial activity comprising a bactericidal/permeability-increasing (BPI) protein product and an bactericidal-activity enhancing polyoxyethylene block copolymer surfactant (poloxamer) surfactant or a bacterial and fungal growth-inhibiting enhancing poloxamer surfactant, optionally with EDTA, and methods for treating bacterial infection by administering such compositions, alone or concurrently with antibiotics.

1 . In a therapeutic composition comprising a BPI protein product and a stabilizing polyoxypropylene-polyoxyethylene block copolymer (poloxamer) surfactant, the improved composition comprising a bactericidal-activity-enhancing poloxamer surfactant.  
     
     
         2 . The therapeutic composition of  claim 1  further comprising EDTA.  
     
     
         3 . The improved composition of  claim 1  wherein the bactericidal-activity-enhancing poloxamer surfactant is selected from the group consisting of poloxamer 333, poloxamer 334, poloxamer 335, and poloxamer 403.  
     
     
         4 . The therapeutic composition of  claim 3  further comprising EDTA.  
     
     
         5 . In a method for treating a bacterial infection comprising administering a composition of BPI protein product and a stabilizing polyoxypropylene-polyoxyethylene block copolymer (poloxamer) surfactant, the improvement comprising administering a therapeutic composition of BPI protein product and bactericidal-activity-enhancing poloxamer surfactant.  
     
     
         6 . The improved method of  claim 5  wherein the therapeutic composition further comprises EDTA.  
     
     
         7 . The improved method of  claim 5  wherein the bactericidal-activity-enhancing poloxamer surfactant is selected from the group consisting of poloxamer 333, poloxamer 334, poloxamer 335, and poloxamer 403.  
     
     
         8 . The improved method of  claim 5  further comprising administering an antibiotic.  
     
     
         9 . A composition for inhibiting bacterial and fungal growth comprising a BPI protein product and a bacterial and fungal growth-inhibiting enhancing poloxamer surfactant.  
     
     
         10 . The composition of  claim 9  further comprising EDTA.  
     
     
         11 . The composition of  claim 9  wherein the bacterial and fungal growth-inhibiting enhancing poloxamer surfactant is selected from the group consisting of poloxamer 333, poloxamer 334, poloxamer 335, and poloxamer 403.  
     
     
         12 . A method for inhibiting bacterial and fungal growth comprising treating the bacteria or fungus with a composition of a BPI protein product and a bacterial and fungal growth-inhibiting enhancing poloxamer surfactant.  
     
     
         13 . The method of  claim 12  wherein the composition further comprises EDTA.  
     
     
         14 . The method of  claim 12  wherein the bacterial and fungal growth-inhibiting enhancing poloxamer surfactant is selected from the group consisting of poloxamer 333, poloxamer 334, poloxamer 335, and poloxamer 403.